Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

医学 放射免疫疗法 骨髓 髓系白血病 核医学 随机对照试验 白血病 内科学 造血干细胞移植 肿瘤科 耐火材料(行星科学) 放射治疗 髓样 移植 免疫学 单克隆抗体 抗体 物理 天体生物学
作者
Susan Passalaqua,Mona Natwa,Ming-Kai Chen,Robert H. Wagner,Wendell Yap,Landis K. Griffeth,Gregory A. Wiseman,Joyce Mhlanga,Richard L. Wahl,Norbert Avril,Robert S. Hellman,Dominick Lamonica,Manuela Matesan,Beth Chasen,Neil J. Hansen,Eugene Leung,Joseph R. Osborne,Jennifer Peterson,Yusuf Menda,Dinko Franceschi,Qing Liang,Vijay Reddy,Mark S. Berger,Neeta Pandit‐Taskar
摘要

82 Background: Patients ≥ 55 years of age with high-risk acute myeloid leukemia (AML) may benefit from an allogeneic hematopoietic stem cell transplantation (HSCT), which is often the only potentially curative therapy available. However, complete remission (CR) is usually a prerequisite for most centers to perform HSCT, as CR predicts an optimal outcome. Many older patients with relapsed/refractory (R/R) AML do not receive HSCT, as they do not achieve the required CR. Additionally, many are unable to tolerate the myeloablative conditioning required for eradication of disease. While the reduced intensity conditioning is better tolerated, it often exhibits high rates of relapse. SIERRA trial is a prospective, randomized, phase 3 trial for older patients with R/R AML to address this unmet need. Iomab-B (131I labeled apamistamab) targets CD45, which is highly expressed in leukemia cells. We hypothesized that the targeted delivery of therapeutic Iomab-B with an imaging-based dosimetry enables successful engraftment despite active disease in the marrow.Methods: Eligible patients with active R/R AML, adequate organ function, and related/unrelated 8/8 HLA-matched donors were randomized (1:1) to the Iomab-B or Conventional Care (CC) arm. Patients randomized to Iomab-B received a low dose of Iomab-B, followed by 3 sequential gamma camera images (Fig 1) to determine the personalized therapeutic dose that would deliver maximal radiation to the marrow while limiting the liver dose to 24 Gy. Dosimetry was performed using serial imaging data and Olinda program (V2.1, Hermes Medical). Following a therapeutic infusion of Iomab-B and a non-myeloablative conditioning backbone of fludarabine (30 mg/m2 x 3) and 2 Gy Total Body Irradiation, HSCT was performed 12-14 days later. Each patient on the CC arm received the investigator’s choice of non-radioactive salvage therapy and could proceed to HSCT if they achieved CR. If no CR, the study allowed patients to cross over and receive Iomab-B-based conditioning followed by allogeneic HSCT. Patient age, donor type, bone marrow cellularity, blast percentage, type of donor, stem cell dose, administered Iomab-B activity (mCi), and radiation dose to marrow (Gy), were analyzed for a relationship to days to engraftment among each group. Results: Preliminary data were available from 113 patients (Table 1). 56 patients were randomized to Iomab-B for which 49 patients received allogeneic transplant. In the CC arm, 82% (47/57) of patients failed salvage therapy. 30 of the 47 (64%) CC patients crossed over and received Iomab-B followed by allogeneic HSCT. Median time to neutrophil and platelet engraftment were 14 days (range 9-22) and 18 days (range 4-39), respectively, in Iomab-B group, with 89% of evaluable patients achieving full donor chimerism (> 95% by day 100). All patients who received Iomab-B treatment achieved engraftment, including the Iomab-B group and the cross-over patients. Neither the radiation dose delivered to marrow (median 14.7 Gy; range 4.6-32 Gy) nor the administered activity (median 646 mCi; range 354-1027 mCi) showed correlation with the time to either neutrophil (p = 0.525) or platelet engraftment (p = 0.952). Regression analyses, considering all the variables individually, did not indicate a statistically significant correlation (p > 0.1) between days to engraftment and marrow dose. These results were consistent for the cross-over group. Furthermore, the marrow radiation dose did not show a significant correlation with % chimerism at day 28 in patients on the Iomab-B arm or in cross-over patients. Conclusion: No significant relationship between total administered activity or radiation dose to marrow with the speed of engraftment was found, indicating the dosimetry estimates for ablative doses appear to be adequate and successful in ablation, despite a heavy leukemia burden prior to HSCT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zongzi12138完成签到,获得积分0
刚刚
刚刚
王哈哈完成签到,获得积分10
刚刚
香蕉觅云应助人间不清醒采纳,获得30
2秒前
5秒前
6秒前
bzdjsmw完成签到 ,获得积分10
6秒前
WebCasa应助旦皋采纳,获得10
6秒前
路易斯完成签到,获得积分10
7秒前
颜愫发布了新的文献求助10
7秒前
萌萌完成签到,获得积分10
8秒前
研友_X89o6n完成签到,获得积分10
10秒前
Ther发布了新的文献求助10
12秒前
哈哈哈完成签到,获得积分10
13秒前
15秒前
诚心的初露完成签到,获得积分10
15秒前
lyb完成签到 ,获得积分10
17秒前
风中方盒完成签到,获得积分20
17秒前
布丁圆团完成签到,获得积分10
18秒前
yikeshu完成签到,获得积分10
18秒前
Zoe完成签到 ,获得积分10
19秒前
21秒前
星辰大海应助do0采纳,获得10
22秒前
tt完成签到 ,获得积分10
23秒前
浅辰完成签到,获得积分10
24秒前
大气萤完成签到,获得积分20
25秒前
25秒前
我ppp完成签到 ,获得积分10
25秒前
26秒前
易燃物品完成签到,获得积分10
26秒前
Hello应助Ther采纳,获得10
28秒前
CherylZhao完成签到,获得积分10
29秒前
Galato发布了新的文献求助10
30秒前
颜愫完成签到,获得积分10
30秒前
安详向日葵完成签到 ,获得积分10
31秒前
拼搏的白云完成签到,获得积分10
31秒前
852应助hhh采纳,获得10
31秒前
李白白白完成签到,获得积分10
31秒前
王手完成签到,获得积分10
31秒前
32秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029